Open AccessEfficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
Author(s) -
Atakan Demir,
Nil Molınas Mandel,
Semra Paydaş,
Gökhan Demir,
Özlem Er,
Nazım Serdal Turhal,
Sevil Bavbek,
Yeşim Eralp,
Pınar Saip,
Emine Güler,
Adnan Aydıner,
Başak Oyan Uluç,
Sadettin Kılıçkap,
Necdet Üskent,
Nuri Karadurmuş,
Mehmet Kaplan,
Mustafa Teoman Yanmaz,
Hacer Demir,
Özkan Alan,
Taner Korkmaz,
Polat Olgun,
Özlem Sönmez Uysal,
Kadri̇ Altundağ,
Şeyda Gündüz,
Meral Günaldı,
Murat Sarı,
İsmail Beypınar,
Gül Başaran
Publication year - 2020
Publication title -
balkan medical journal/balkan medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.398
H-Index - 16
eISSN - 2146-3131
pISSN - 2146-3123
DOI - 10.4274/balkanmedj.galenos.2020.2019.11.143
Subject(s) - palbociclib , medicine , metastatic breast cancer , breast cancer , oncology , retrospective cohort study , cancer , adverse effect , population , gynecology , environmental health
The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood.